DEBEQUIN-C AD 1 JBE .300/2G/100 ML Afecciones Oftalmicas Carcinoma hepatocelular tratado previamente con

Description

Carcinoma hepatocelular tratado previamente con sorafenib

PRINCIPIO ACTIVO: CICLOBENZAPRINA - CLONIXINATO DE LISINA

SUSTANCIA: APODEFIL TAB

PRINCIPIO ACTIVO: RISEDRONATO SÓDICO

Características de VELSAY-S:

DEBEQUIN-C AD 1 JBE .300/2G/100 ML Afecciones Oftalmicas Carcinoma hepatocelular tratado previamente con

Exchange/Return Notes

We offer a 30-day return/exchange service after receiving.
Final sale items are not eligible for returns or exchanges.
To process your return/exchange, please contact us at [email protected]
Please click here for more details>>> Return & Exchange Policy